IQVIA (NYSE:IQV) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

IQVIA (NYSE:IQV) had its target price upped by JPMorgan Chase & Co. from $225.00 to $285.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the medical research company’s stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 15.65% from the stock’s previous close.

Other equities analysts also recently issued research reports about the company. Barclays reissued an “overweight” rating on shares of IQVIA in a research report on Tuesday. Mizuho boosted their price objective on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Morgan Stanley reiterated an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. HSBC reiterated a “buy” rating and set a $240.00 price target on shares of IQVIA in a research report on Monday, July 6th. Finally, Robert W. Baird boosted their price objective on shares of IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research report on Wednesday. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.

IQVIA Trading Up 1.4%

Shares of IQV traded up $3.49 during trading hours on Wednesday, reaching $246.43. The stock had a trading volume of 1,319,378 shares, compared to its average volume of 1,812,333. The company has a market cap of $41.13 billion, a P/E ratio of 30.48, a P/E/G ratio of 1.91 and a beta of 1.20. IQVIA has a 52 week low of $154.50 and a 52 week high of $251.36. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm has a 50-day moving average of $190.47 and a 200 day moving average of $186.86.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company’s revenue was up 8.7% on a year-over-year basis. During the same period in the previous year, the firm earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts expect that IQVIA will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has approved a share repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Hedge Funds Weigh In On IQVIA

A number of hedge funds have recently bought and sold shares of IQV. Vanguard Group Inc. grew its stake in IQVIA by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock valued at $4,429,426,000 after purchasing an additional 159,899 shares during the period. Geode Capital Management LLC lifted its stake in IQVIA by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock worth $982,272,000 after purchasing an additional 24,453 shares in the last quarter. Boston Partners increased its position in shares of IQVIA by 14.9% in the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock worth $923,276,000 after purchasing an additional 530,672 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of IQVIA by 16.2% during the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock worth $856,468,000 after acquiring an additional 528,753 shares during the last quarter. Finally, Invesco Ltd. increased its stake in IQVIA by 15.3% in the third quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock valued at $526,891,000 after acquiring an additional 367,204 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting IQVIA

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: IQVIA reported second-quarter adjusted earnings of $3.15 per share, ahead of the roughly $3.02–$3.03 analyst consensus, while revenue rose 8.7% year over year to $4.37 billion, exceeding expectations of approximately $4.30 billion. IQVIA Reports Second-Quarter 2026 Results
• Positive Sentiment: The company raised its FY 2026 adjusted EPS guidance to $12.80–$13.00, above the prior consensus of $12.57, and provided revenue guidance of $17.3–$17.5 billion. Management cited broad-based growth, strong clinical-research demand and record R&D bookings. IQV Q2 Earnings Beat Estimates on R&D Bookings, Guidance Raised
• Positive Sentiment: Analyst sentiment strengthened following the report. Robert W. Baird raised its price target from $252 to $287 and maintained an “outperform” rating, implying additional upside based on the cited share price. Baird Raises IQVIA Price Target
• Neutral Sentiment: IQVIA’s earnings beat and guidance increase have put fair value and valuation back in focus. The stock is trading near its 52-week high, with a reported P/E ratio around 30, so continued gains may depend on the company sustaining its growth and bookings momentum. IQVIA Holdings Earnings Beat Keeps Fair Value in Focus

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.